ReviewInternational journal of molecular sciences2021
Mitochondrial Lipid Homeostasis at the Crossroads of Liver and Heart Diseases.
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 36 citations in OpenAlex.
- Metabolic Reprogramming of Cancer Stem Cells: Targeting Lipid Flux and Mitochondrial Plasticity to Overcome Therapeutic Resistance.Cancer medicine · 2026Review
- Article
- Alcalase-hydrolyzed casein peptides after simulated gastrointestinal digestion alleviate high-fat diet-induced metabolic dysfunction in mice.Frontiers in nutrition · 2026Article
- Article
- Gene Therapy Approaches for Atherosclerosis Focusing on Targeting Lipid Metabolism and Inflammation.International journal of molecular sciences · 2025Review
- Naphthenic Acid Fraction Components-Induced Metabolic and Mitochondrial Alterations in Rat Hepatoma Cells: Monitoring Metabolic Reprogramming with Tryptophan-Kynurenine Ratio.Journal of xenobiotics · 2025Article
- The protein kinases family in fungi: adaptability, virulence and conservation between species.Frontiers in microbiology · 2025Review
- Excessive alcohol consumption: a driver of metabolic dysfunction and inflammation.Frontiers in toxicology · 2025Review
- Positive correlations between TyG and TyG-BMI indices and the risk of NAFLD and degree of liver fibrosis in patients undergoing PCI.Frontiers in endocrinology · 2025Article
- Exosomes in Atherosclerosis: Role in the Pathogenesis and Targets for Therapy.Current medicinal chemistry · 2025Review
- Exploring novel roles of lipid droplets and lipid metabolism in regulating inflammation and blood-brain barrier function in neurological diseases.Frontiers in neuroscience · 2025Review
- Common Denominator of MASLD and Some Non-Communicable Diseases.Current issues in molecular biology · 2024Review
- Association between atherosclerosis and the development of multi-organ pathologies.SAGE open medicine · 2024Review
- Steamed daylily flower (Hemerocallis fulva L.) protected cardiac and hepatic cells against ethanol induced apoptotic and oxidative damage.Journal of food and drug analysis · 2023Article
- Mitochondrial Dysfunction-Associated Mechanisms in the Development of Chronic Liver Diseases.Biology · 2023Review
- A high-fat diet increases hepatic mitochondrial turnover through restricted acetylation in a NAFLD mouse model.American journal of physiology. Endocrinology and metabolism · 2023Article
- Hepatic Mitochondria-Gut Microbiota Interactions in Metabolism-Associated Fatty Liver Disease.Metabolites · 2023Review
- The newly proposed alanine aminotransferase to high-density lipoprotein cholesterol ratio has shown effectiveness in identifying non-alcoholic fatty liver disease.Frontiers in endocrinology · 2023Article
- Impact of Dysfunctional Adipose Tissue Depots on the Cardiovascular System.International journal of molecular sciences · 2022Review
- Pathophysiological mechanisms of cardiovascular disorders in non-alcoholic fatty liver disease.Gastroenterology and hepatology from bed to bench · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 3 countries.
Funding
Abstract
The prevalence of NAFLD (non-alcoholic fatty liver disease) is a rapidly increasing problem, affecting a huge population around the globe. However, CVDs (cardiovascular diseases) are the most common cause of mortality in NAFLD patients. Atherogenic dyslipidemia, characterized by plasma hypertriglyceridemia, increased small dense LDL (low-density lipoprotein) particles, and decreased HDL-C (high-density lipoprotein cholesterol) levels, is often observed in NAFLD patients. In this review, we summarize recent genetic evidence, proving the diverse nature of metabolic pathways involved in NAFLD pathogenesis. Analysis of available genetic data suggests that the altered operation of fatty-acid β-oxidation in liver mitochondria is the key process, connecting NAFLD-mediated dyslipidemia and elevated CVD risk. In addition, we discuss several NAFLD-associated genes with documented anti-atherosclerotic or cardioprotective effects, and current pharmaceutical strategies focused on both NAFLD treatment and reduction of CVD risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.